New hope for AML patients: drug combo trial launches
NCT ID NCT05287568
First seen Jan 15, 2026 · Last updated May 14, 2026 · Updated 19 times
Summary
This early-stage trial tests a combination of two drugs, CC-486 and venetoclax, in people with acute myeloid leukemia (AML) whose cancer has returned or not responded to treatment, as well as some newly diagnosed patients. The main goal is to find the safest dose of CC-486 when given with venetoclax. Researchers will also monitor side effects. About 35 participants will take part in this study at one location.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AML are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
CU Anschutz Medical Campus
RECRUITINGAurora, Colorado, 80045, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Email: •••••@•••••
-
University of Colorado Hospital
RECRUITINGAurora, Colorado, 80045, United States
Contact
Contact
Contact
Contact Email: •••••@•••••
Contact
Contact
Contact Email: •••••@•••••
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Conditions
Explore the condition pages connected to this study.